Literature DB >> 19785528

Preoperative percutaneous stone surgery in patients receiving anticoagulant therapy.

Andreas J Gross1, T Bach.   

Abstract

Percutaneous nephrostolithotomy (PCNL) is an essential component in the management of large volume renal calculi. Either in combination with shockwave lithotripsy but especially as monotherapy, PCNL is recommended as the most effective treatment option for patients with staghorn calculi or large volume stone disease. Multiple tracts allow successful management of nearly every stone burden in a single surgical session. Furthermore, patients with anatomic variations (eg, horseshoe kidney) can be treated by PCNL successfully. Overall stone-free rates of above 78% are described. With the rising age of the overall patient population, another problem occurs. Increasing age frequently leads to an increase in comorbidities; for example, patients receiving anticoagulation may need treatment for stones, which can pose a dilemma. The aim of this review was to provide an overview of thrombotic risk, depending on the underlying disease, and to propose a clinical pathway on how to deal with this selected group of patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19785528     DOI: 10.1089/end.2009.1519

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  3 in total

1.  [Complications in percutaneous lithotomy].

Authors:  M Ritter; M-C Rassweiler; M S Michel
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 2.  Stone management for the patient on anticoagulation.

Authors:  Julie M Riley; Timothy D Averch
Journal:  Curr Urol Rep       Date:  2012-06       Impact factor: 3.092

Review 3.  Thromboprophylaxis and bleeding diathesis in minimally invasive stone surgery.

Authors:  Andreas Bourdoumis; Theodora Stasinou; Stefanos Kachrilas; Athanasios G Papatsoris; Noor Buchholz; Junaid Masood
Journal:  Nat Rev Urol       Date:  2013-12-17       Impact factor: 14.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.